Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 687 across all filing types
Latest filing 2021-01-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Appendix 4C and Activity Report 8 pages 547.5KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Quarterly Cash Flow Statement & Operational Highlights' for Recce Pharmaceuticals Ltd, covering the December 2020 quarter. It includes detailed financial data such as cash flows from operating, investing, and financing activities, cash balances, and operational updates including clinical trial approvals and patent grants. The presence of the Appendix 4C cash flow report, which is a regulatory requirement for quarterly reporting on cash flows for ASX-listed entities, confirms this is a quarterly financial report. The document is comprehensive, with substantive financial data and operational commentary for the quarter, not merely an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2021-01-27 English
Appendix 2A 15 pages 203.9KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes details about the entity, the type of securities being quoted, and references to ASX Listing Rules and Corporations Act sections. This type of document is a regulatory announcement related to securities issuance and quotation, not a financial report or detailed financial statement. It is a formal notification to the exchange about new securities being issued or converted, typically classified as a regulatory filing. The document length is 15,000 characters, but the content is procedural and announcement-based, not a report or financial statement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-01-18 English
Cleansing Statement 1 page 267.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement titled 'Cleansing notice under section 708A of the Corporations Act'. It details the issuance of fully paid ordinary shares and compliance statements under the Corporations Act. The content is a regulatory compliance notice related to share issuance, not a full financial report or detailed capital update. It is short (1259 characters) and serves as a formal regulatory announcement rather than a report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-01-18 English
Corporate Presentation 29 pages 4.8MB
Investor Presentation Classification · 95% confidence The document is titled '10th Annual Corporate Access Event' and is dated January 2021. It contains detailed information about Recce Pharmaceuticals Ltd, including company background, capital structure, board and management details, product pipeline, clinical trials, and market positioning. The content is structured as a presentation with disclaimers, future outlook, and detailed business and scientific information. There is no indication that this is a full annual report or financial statements. Instead, it is a detailed presentation aimed at investors, likely used during a corporate access event to inform and attract investment. The length (15,000 characters) and detailed content support that this is a full presentation document rather than a brief announcement or regulatory filing. Therefore, the document best fits the category of an Investor Presentation (IP).
2021-01-07 English
Positive Intranasal Animal Data against SARS-CoV-2 in Study 3 pages 559.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 23 December 2020 from Recce Pharmaceuticals Ltd reporting positive intranasal animal data against SARS-CoV-2. It details study results on antiviral activity in hamsters, describing experimental design, outcomes, and future plans. The content is a news release about scientific study results and company updates on its COVID-19 related research. It does not contain financial statements, regulatory certifications, voting results, or management changes. It is not a full financial report, audit, or earnings release. The document is a corporate announcement of scientific data and progress, fitting best under a general regulatory announcement category rather than a specific financial or governance report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-12-22 English
Business Update 3 pages 447.5KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement titled 'Recce Pharmaceuticals Business Update' dated 16 December 2020. It provides updates on clinical trials, research progress, and financial position (balance sheet) but does not contain detailed financial statements or comprehensive financial analysis. The length is 4321 characters, which is relatively short and typical for a business update announcement. There is no indication that this is a full annual or interim report, earnings release, or regulatory filing. The content focuses on operational progress and clinical program updates, which aligns with a Capital/Financing Update or general business update. Given the focus on clinical progress and financial position mention, the best fit is Capital/Financing Update (CAP).
2020-12-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.